Plain-English translation of NCT06234605 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called , either alone or combined with (an existing kidney cancer drug). Researchers want to find the right dose and learn whether this combination works better than the existing treatment alone for people with advanced kidney cancer.
Current kidney cancer treatments don't work for everyone, and some patients develop resistance over time. This trial exists to explore whether adding a new medication to an approved treatment might help more patients control their disease.
You likely qualify if…
You likely don't qualify if…
You would visit the research center regularly (usually weekly at first, then monthly) to take the medication daily, have blood tests, and be monitored for side effects. The trial has three parts: some people take the new medication alone, others take it combined with the existing drug at increasing doses, and others take a final tested dose combination. Your involvement would likely last several months to over a year, depending on how well the treatment works for you.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States